-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca's Sone-Ve cuts death risk 42% in advanced gastric cancer trial

PUBT·10/25/2026 15:35:51
Listen to the news
AstraZeneca's Sone-Ve cuts death risk 42% in advanced gastric cancer trial
  • AstraZeneca’s investigational sonesitatug vedotin improved overall survival versus investigator-selected treatment in the Phase III CLARITY-Gastric01 trial for previously treated CLDN18.2-positive advanced gastric cancers.
  • Survival benefits extended across CLDN18.2 expression levels, supporting potential use in a broader patient population.
  • Progression-free survival assessed by independent review did not reach statistical significance.
  • Severe treatment-related adverse events were less frequent with sonesitatug vedotin, with no new safety signals identified.
  • Results will be presented today at the European Society for Medical Oncology Congress 2026 in Madrid.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610251135BIZWIRE_USPR_____20261025_BW681931) on October 25, 2026, and is solely responsible for the information contained therein.